Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CLARITHROMYCIN

All products: general benefit

Other products in the same Health Canada class (J01FA) — coverage varies; not interchangeable

  • Azithromycin (Zithromax): general benefit, Limited Use 549, Not a benefit
  • Erythromycin base (Erythromid): general benefit, Not a benefit
  • Erythromycin estolate (Ilosone): general benefit, Not a benefit
  • Erythromycin ethylsuccinate (Ees-200): general benefit, Not a benefit

Biaxin · DIN 02146908 · 125mg/5mL · Ped Gran

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Biaxin (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Biaxin · DIN 02146908 Manufacturer: BGP Pharma ULC; listing date 1997-08-28 Daily cost (source): $3.5000 Health Canada: Marketed since 2016-04-08 · brand BIAXIN · ATC J01FA09 CLARITHROMYCIN · form Granules for suspension · route Oral · ingredients CLARITHROMYCIN 125 MG/5ML · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2388 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18066 · Verify on the e-Formulary ↗ (DIN 02146908)

Source record
DIN 02146908: Biaxin Raw flags: sec3=Y Item: 081212030; group id 21; item number 0033; lccId None; manufacturer id BGP Source form: Ped Gran; strength: 125mg/5mL Recorded listing: General benefit Source prices (unrounded): $0.3500; ministry $0.2388 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02146908 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18066
Interchangeable products
Taro-Clarithromycin · DIN 02390442 · $0.2388
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (08:12:12 Erythromycins) and how they are covered

Matched class: 08:12:12 Erythromycins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): AZITHROMYCIN, ERYTHROMYCIN BASE, ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ETHYLSUCCINATE 08:12:12 Erythromycins

AZITHROMYCIN

· 28 products · Listed, not a benefit (6), General benefit (21), Limited Use, codes 549 (1) · strengths: 100mg/5mL, 200mg/5mL, 250mg, 600mg · O/L-15mL Pk, O/L-22.5mL Pk, O/L-37.5mL Pk, Tab

ERYTHROMYCIN BASE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Tab

ERYTHROMYCIN ESTOLATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg/mL · O/L

ERYTHROMYCIN ETHYLSUCCINATE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 40mg/mL, 80mg/mL · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:12
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: infections
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CIPROFLOXACIN AND DEXAMETHASONE · Limited Use, codes 509 INDICATIONS AND CLINICAL USE CIPRODEX® (ciprofloxacin/dexamethasone otic suspension) is indicated for the treatment of infections caused by most strains of the designated microorganisms in the specific conditions listed below: Acute Otitis Media with Otorrhea through tympanostomy tubes in pediatric patients ≥ 6 months of age due to: Aerobic, Gram-Positive: Streptococcus pneumoniae Staphylococcus aureus Aerobic, Gram-Negative: Haemophilus influenza Moraxella catarrhalis Pseudomonas aeruginosa Acute Otitis Externa in adults and pediatric patients ≥ 1 year of age due to: Aerobic, Gram-Positive: Staphylococcus aureus Aerobic, Gram-Negative: Pseudomonas aeruginosa To reduce the development of drug-resistant bacteria and maintain the effectiveness of CIPRODEX and other antibacterial drugs, CIPRODEX should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. PM: https://pdf.hres.ca/dpd_pm/00041611.PDF; date September 27, 2017; DIN 02252716; fetched 2026-09-10 Product monograph TETRACYCLINE · Listed, not a benefit (1), General benefit (1) Indications TETRACYCLINE (tetracycline hydrochloride capsules) is indicated for infections caused by the following microorganisms: • Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, tick fevers), M. pneumoniae (PPLO, Eaton agent), agents of psittacosis and ornithosis, agents of L. venereum and G. inguinale, and the spirochetal agent of relapsing fever (B. recurrentis). PM: https://pdf.hres.ca/dpd_pm/00084169.PDF; date 2026-03-17; DIN 00580929; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS BIAXIN BID® (clarithromycin tablets USP, film-coated) BIAXIN BID® may be indicated in the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the diseases listed below: • Upper Respiratory Tract • Pharyngiitis/tonsillitis, caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). • Acute maxillary sinusitis caused by Streptococcus pneumoniae (S. pneumoniae), Haemophilus influenzae (H. influenzae), and Moraxella (Branhamella) catarrhalis [M. (Branhamella) catarrhalis]. • Lower Respiratory Tract • Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae (including beta-lactamase producing strains), M. (Branhamella) catarrhalis (including beta- lactamase producing strains). • Pneumonia caused by S. pneumoniae and Mycoplasma. pneumoniae (M. pneumoniae). See WARNINGS AND PRECAUTIONS, Susceptibility/Resistance. • Uncomplicated Skin and Skin Structure Infections • Uncomplicated Skin and Skin Structure Infections caused by Streptococcus pyogenes (S. pyogenes), Staphylococcus aureus… https://pdf.hres.ca/dpd_pm/00078094.PDF PM date: DEC 17, 2024 Source product: BIAXIN BID; DIN 01984853; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.